2023-08-25 19:33:11
The results of a phase 3 trial called STEP HFpEF were presented today, revealing that a weekly dose of 2.4 mg semaglutide has shown promising results in improving the health of adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The study, presented at the European Society of Cardiology (ESC) Congress and published in the New England Journal of Medicine, demonstrated significant reductions in symptoms related to heart failure, physical limitations, and improvements in participants’ mobility. Additionally, the treatment resulted in substantial weight loss.
HFpEF, which accounts for half of all heart failure cases, is characterized by a high disease burden and physical limitations that can greatly impact daily life. These symptoms include fatigue, shortness of breath, reduced movement, and edema in the extremities. Furthermore, the majority of people with HFpEF are overweight or obese, which is associated with even more severe symptoms and a reduced quality of life.
The results of this trial offer hope for patients with HFpEF and obesity, as current treatment options are limited. Dr. Mikhail Kosiborod, the principal investigator of the study, expresses optimism that these findings could potentially change the approach to managing HFpEF in obese individuals.
Aside from improvements in symptoms and physical function, the study also observed significant weight loss in participants who received the semaglutide dose compared to those who received a placebo. Furthermore, the semaglutide group exhibited an increase in walking distance and a decrease in inflammation.
The safety profiles of the treatment were consistent with previous studies, with participants who received semaglutide experiencing fewer serious side effects.
HFpEF is a prevalent form of heart failure, often associated with being overweight or obese. Despite advancements in treatment, there are still unmet needs for this patient population, making this research crucial in enhancing our understanding and management of the condition.
The research featured in this study was funded by Novo Nordisk, a pharmaceutical company specializing in chronic diseases.
Janine Budding, author of this report, is an expert in interactive healthcare news. She aims to provide healthcare providers with daily updates on news relevant to their field. With a background in physiotherapy and healthcare business administration, as well as experience in various positions within the healthcare and pharmaceutical industry, Budding stays informed through attending leading medical conferences to keep her knowledge up-to-date. She is currently pursuing a Masters in Applied Psychology, and her views expressed in this article are personal and do not represent any employer or client.
]
#Significant #improvement #demonstrated #STEP #HFpEF #study